Kuerten has an average return of 1.7% when recommending Qiagen.
According to TipRanks.com, Kuerten is ranked #6927 out of 7949 analysts.
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $48.44, which is a 2.4% upside from current levels. In a report released today, Deutsche Bank also maintained a Buy rating on the stock.
Based on Qiagen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $628 million and net profit of $155 million. In comparison, last year the company earned revenue of $567 million and had a net profit of $129 million.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN: